Annotation Detail
Information
- Associated Genes
- DPYD
- Associated Variants
-
DPYD c.1905+1G>A
(
ENST00000370192.8 )
DPYD c.1905+1G>A ( ENST00000370192.8 ) - Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67376798 and the FDA drug labels warn to use precautions in this patient population.
- Variant Origin
- Common Germline
- Variant Origin
- Common Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1800
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1526
- Variant URL
- https://civic.genome.wustl.edu/links/variants/737
- Rating
- 5
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Tegafur,Fluorouracil,Capecitabine
- Evidence Level
- A
- Clinical Significance
- Adverse Response
- Pubmed
- 23988873
Drugs
Drug Name | Sensitivity | Supported |
---|---|---|
Tegafur | Adverse Response | true |
Fluorouracil | Adverse Response | true |
Capecitabine | Adverse Response | true |